Texas Biotech changes name to Encysive Pharma

Texas Biotechnology says that, following approval by its shareholders, its corporate name is changed to Encysive Pharmaceuticals, effective May 16. In conjunction with the name change, on May 19 the company's Nasdaq ticker symbol will change to ENCY and its corporate web site address will become www.encysive.com.

"Our new identity better reflects our optimism, strategic focus and aspirations to achieve profitability," said chief executive Bruce Given. "Changing our name to Encysive Pharmaceuticals should facilitate our efforts as we reach out to new audiences in our drive towards commercialization of sitaxsentan, our once-daily, selective endothelin antagonist for the treatment of pulmonary arterial hypertension," he noted.